Shares of Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) plummeted $1.20 to 90 cents after its drug candidate to treat cocaine addiction failed to meet trial goals.
Catalyst's Drug Candidate Fails Trial
May 29, 2009 at 13:57 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.